Suppr超能文献

新冠病毒疫苗接种后的突破性感染:见解、观点与挑战。

Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges.

作者信息

Amanatidou Evropi, Gkiouliava Anna, Pella Eva, Serafidi Maria, Tsilingiris Dimitrios, Vallianou Natalia G, Karampela Irene, Dalamaga Maria

机构信息

Laboratory of Biomathematics, School of Medicine, University of Thessaly, Larissa, Greece.

First Department of Propaedeutic Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece.

出版信息

Metabol Open. 2022 Mar 17;14:100180. doi: 10.1016/j.metop.2022.100180. eCollection 2022 Jun.

Abstract

Vaccination programs against SARS-CoV-2 constitute the mainstay of public health interventions against the global COVID-19 pandemic. Currently available vaccines have shown 90% or better rates of protection against severe disease and mortality. Barely a year after vaccines became available, the Omicron variant and its unprecedented speed of transmission has posed a new challenge. Overall, Omicron presents increased immune escape, transmissibility, and decreased pathogenicity. Vaccines do not offer a full protection against SARS-CoV-2 acquisition, since "breakthrough" infections may occur in fully vaccinated individuals, who may in turn spread the virus to others. Breakthrough infections may be causally related to the viral profile (viral variant and load, incubation period, transmissibility, pathogenicity, immune evasion), immunity characteristics (mucosal versus systemic immunity, duration of immunity, etc.), host determinants (age, comorbidities, immune status, immunosuppressive drugs) and vaccination properties (platform, antigen dose, dose number, dose interval, route of administration). Determining the rate of breakthrough infections may be challenging and necessitates the conduction of population-based studies regarding vaccine effectiveness as well as neutralizing antibody testing, a surrogate of immune protection. In this review, we analyze the causes of breakthrough infections, their clinical consequences (severity of infection and transmission), methods of determining their incidence as well as challenges and perspectives. Long COVID as well as multi-inflammatory syndrome in adolescents may be significantly reduced in breakthrough infections. The need for universal pancoranavirus vaccines that would aim at protecting against a plethora of SARS-CoV-2 variants as well as emerging variants is discussed. Finally, novel vaccine strategies, such as nasal vaccines, may confer robust mucosal and systemic protection, reducing efficiently transmission.

摘要

针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的疫苗接种计划是全球应对2019冠状病毒病(COVID-19)大流行的公共卫生干预措施的支柱。目前可用的疫苗已显示出对重症疾病和死亡的保护率达到90%或更高。在疫苗可用后不到一年,奥密克戎变种及其前所未有的传播速度带来了新的挑战。总体而言,奥密克戎表现出免疫逃逸增加、传播性增强和致病性降低。疫苗并不能完全防止感染SARS-CoV-2,因为在完全接种疫苗的个体中可能会发生“突破性”感染,这些个体可能会将病毒传播给他人。突破性感染可能与病毒特征(病毒变种和载量、潜伏期、传播性、致病性、免疫逃逸)、免疫特性(黏膜免疫与全身免疫、免疫持续时间等)、宿主决定因素(年龄、合并症、免疫状态、免疫抑制药物)和疫苗特性(平台、抗原剂量、剂量数量、剂量间隔、给药途径)存在因果关系。确定突破性感染的发生率可能具有挑战性,需要开展基于人群的疫苗效力研究以及中和抗体检测,中和抗体检测是免疫保护的替代指标。在本综述中,我们分析了突破性感染的原因、其临床后果(感染严重程度和传播情况)、确定其发生率的方法以及挑战和前景。突破性感染中,长期新冠以及青少年多炎症综合征可能会显著减少。文中还讨论了研发通用泛冠状病毒疫苗的必要性,这类疫苗旨在预防多种SARS-CoV-2变种以及新出现的变种。最后,新型疫苗策略,如鼻用疫苗,可能会提供强大的黏膜和全身保护,有效减少传播。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/01db/8935496/373b2b51875b/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验